{
  "id": "CD004762.PUB3",
  "draft": "How effective and safe are medicines for treating muscle stiffness (myotonia) in people with myotonic disorders?\n\nKey messages\n- Mexiletine can reduce muscle stiffness in non‑dystrophic myotonia and may improve hand‑grip strength, but it does not clearly change how patients feel their stiffness. Common side‑effects are stomach upset, tiredness and headache.\n- Lamotrigine may speed up muscle relaxation and improve overall wellbeing in non‑dystrophic myotonia, but it can cause headache, fatigue and rash. Other drugs such as phenytoin, imipramine and similar agents showed little or uncertain benefit because the studies were small and of lower quality.\n- More large, high‑quality trials are needed, especially for myotonic dystrophy and for drugs that have not shown clear benefit, to understand long‑term effects and who responds best.\n\nWhat is myotonia and why does it matter?\nMyotonia is a condition where muscles take longer than normal to relax after they have been used. This can cause stiffness, painful cramps, sudden \"locking\" of the muscles, fatigue and reduced ability to move around. The problem is most common in two groups of inherited muscle disorders:\n- Non‑dystrophic myotonia – a genetic problem that mainly affects the muscle’s ion channels (the tiny gates that control the flow of electricity in muscle cells) and leads mainly to myotonia.\n- Myotonic dystrophy – a broader disease that also causes progressive muscle weakness, heart rhythm problems, cataracts and other systemic issues.\nBecause the symptoms can be severe and disabling, people with these conditions often need treatment to improve muscle relaxation and quality of life.\n\nWhat medicines are currently used to treat myotonia?\nDoctors have tried several types of drugs to reduce the delayed muscle relaxation, including:\n- Sodium channel blockers (e.g., mexiletine) – medicines that calm the over‑active electrical signals in muscle cells.\n- Tricyclic antidepressants, benzodiazepines, calcium antagonists, taurine and prednisone – other drug classes that have shown some benefit in small studies.\nThese treatments aim to lessen stiffness and improve daily functioning, but the evidence for how well they work and how safe they are has been uncertain.\n\nWhat did the researchers aim to find out?\nWe asked two main questions:\n1. How effective are drug treatments at reducing the symptoms of myotonia as reported by the people taking the medicines?\n2. How well are these drugs tolerated, meaning what side‑effects they cause and how they affect overall quality of life?\nTo answer these, we searched for randomised controlled trials – the most reliable type of study – that compared any drug for myotonia with a placebo, no treatment or another active drug.\n\nHow did we find the evidence?\nWe searched databases, trial registers, grey literature and consulted experts for studies that compared drug treatments with placebo or other drugs in people with myotonia. We combined the results and rated our confidence in the evidence using the GRADE approach.\n\nWhat did we find?\nWe found 17 trials that tested drugs for myotonia. In total, 392 people took part – 219 had myotonic dystrophy type 1 and 173 had non‑dystrophic myotonia.\n- Mexiletine probably reduces muscle stiffness in non‑dystrophic myotonia, probably shortens the time muscles take to relax, probably improves hand‑grip strength slightly and probably reduces abnormal electrical activity in the muscles. The evidence for these outcomes is of moderate certainty.\n- In myotonic dystrophy, mexiletine probably shortens hand‑grip relaxation time, but we do not have clear evidence that it improves overall clinical myotonia scores.\n- Lamotrigine probably speeds up muscle relaxation and probably improves quality of life in non‑dystrophic myotonia. It also caused headache, fatigue and rash in some participants.\n- Other medicines such as phenytoin, imipramine, procainamide and several others showed little or uncertain benefit because the trials were small and of lower quality.\nCommon side‑effects across the drugs included stomach upset, tiredness, headache, fatigue and rash.\n\nWhat are the limitations of the evidence?\nWe are moderately confident in the evidence because many studies were very small, some participants may have known which treatment they received (which can influence results), and not all trials reported every outcome we were interested in.\n\nHow current is the evidence?\nThis review updates our previous work and includes evidence up to March 2023.\n",
  "metrics": [
    {
      "linguistic_evaluation": {
        "words": {
          "value": 711,
          "rating": "within_limit",
          "direction": null,
          "feedback": null
        },
        "sentences": {
          "value": 33,
          "rating": "info",
          "direction": null,
          "feedback": null
        },
        "words_per_sentence": {
          "value": 21.545454545454547,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "passive_voice": {
          "value": 16,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "active_voice": {
          "value": 73,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "pronouns": {
          "value": 41,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "nominalization": {
          "value": 20,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "nouns": {
          "value": 205,
          "rating": "BEYOND_P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 205.0 to <116.0 (median)"
        },
        "flesch_reading_ease": {
          "value": 50.03471806674338,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "flesch_kincaid_grade": {
          "value": 11.632980437284235,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "automated_readability_index": {
          "value": 12.541630226313771,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "coleman_liau_index": {
          "value": 11.787848101265823,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "gunning_fog_index": {
          "value": 17.844623449686743,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "lix": {
          "value": 54.17555299833781,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "rix": {
          "value": 7.03030303030303,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "smog_index": {
          "value": 15.24744871391589,
          "rating": "BEYOND_P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 15.2 to <12.1 (median)"
        },
        "dale_chall_readability": {
          "value": 8.397346528576909,
          "rating": "P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 8.4 to <7.7 (median)"
        },
        "complex_words_dc": {
          "value": 330,
          "rating": "BEYOND_P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 330.0 to <160.0 (median)"
        },
        "complex_words": {
          "value": 164,
          "rating": "BEYOND_P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 164.0 to <84.0 (median)"
        },
        "long_words": {
          "value": 232,
          "rating": "BEYOND_P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 232.0 to <122.0 (median)"
        }
      },
      "word_count_status": {
        "word_count": 711,
        "limit": 850,
        "status": "within_limit",
        "message": "Word count: 711 ✓ WITHIN LIMIT (≤850 words)"
      },
      "summary": {
        "P25_count": 1,
        "P50_count": 5,
        "P75_count": 6,
        "P90_count": 1,
        "P10_count": 0,
        "BEYOND_P90_count": 5,
        "BELOW_P10_count": 0,
        "total_evaluated": 18,
        "P25_percentage": 5.555555555555555,
        "P50_percentage": 27.77777777777778,
        "P75_percentage": 33.33333333333333,
        "P90_percentage": 5.555555555555555,
        "P10_percentage": 0,
        "BEYOND_P90_percentage": 27.77777777777778,
        "BELOW_P10_percentage": 0,
        "best_quartile_rate": 38.88888888888889,
        "overall_assessment": "MODERATE CONFORMITY WITH PLS PATTERNS"
      }
    }
  ],
  "evaluation": [
    {
      "grade": "NOT_APPROVED",
      "feedback": "The draft passes the required structural checks, but several clarity problems would likely confuse patients:\n1. **Long, repetitive sentence** – \"Mexiletine probably reduces muscle stiffness in non‑dystrophic myotonia, probably shortens the time muscles take to relax, probably improves hand‑grip strength slightly and probably reduces abnormal electrical activity in the muscles.\" This runs 33 words and repeats \"probably\", making it hard to follow. *Rewrite*: \"Mexiletine probably reduces muscle stiffness, shortens the time it takes for muscles to relax, and slightly improves hand‑grip strength. It may also lower abnormal electrical activity in the muscles.\"\n2. **Unexplained technical term** – \"hand‑grip relaxation time\" appears without a plain‑language definition. Patients may not know what this means. *Rewrite*: \"the time it takes for a hand‑grip to return to normal after squeezing.\"\n3. **Evidence certainty wording** – Phrases like \"moderate‑certainty evidence\" are jargon for lay readers. *Rewrite*: \"we have moderate confidence in these results, meaning the evidence is fairly reliable but not definitive.\"\n4. **Methods jargon** – \"grey literature\" and \"GRADE approach\" are not explained. *Rewrite*: \"We also looked at reports that are not published in journals (often called ‘grey literature’) and we used a standard system (GRADE) to judge how trustworthy the evidence is.\"\nThese issues are reflected in the metric analysis: the draft has a high noun count (205, beyond typical PLS), high SMOG (15.2) and Dale‑Chall scores (8.4), and many complex/long words (complex_words = 164, long_words = 232). Reducing noun density and simplifying vocabulary will improve readability. Overall, while the draft meets structural requirements, the identified clarity problems are enough to warrant revision before approval.",
      "pls_evaluation_summary": "The PLS evaluation shows moderate overall conformity but notable deviations: nouns (205, beyond P90), SMOG index (15.2, beyond P90), Dale‑Chall readability (8.4, beyond P90), complex words (164, beyond P90), and long words (232, beyond P90) are all higher than typical PLS patterns, indicating the text is more noun‑heavy and uses many complex/long words than usual."
    }
  ]
}